[go: up one dir, main page]

PT3341379T - Inhibitors of ezh2 - Google Patents

Inhibitors of ezh2

Info

Publication number
PT3341379T
PT3341379T PT167575133T PT16757513T PT3341379T PT 3341379 T PT3341379 T PT 3341379T PT 167575133 T PT167575133 T PT 167575133T PT 16757513 T PT16757513 T PT 16757513T PT 3341379 T PT3341379 T PT 3341379T
Authority
PT
Portugal
Prior art keywords
ezh2
inhibitors
Prior art date
Application number
PT167575133T
Other languages
Portuguese (pt)
Inventor
Dominguez Esteban
Guo Deqi
Margaret Mader Mary
Hannah Nguyen Anh-Quan
Filadelfa Del Prado Miriam
Enrico Richett Michael
John Rodriguez Michael
Yee Mai Yip Yvonne
Yu Kuo-Long
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT3341379T publication Critical patent/PT3341379T/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT167575133T 2015-08-27 2016-08-22 Inhibitors of ezh2 PT3341379T (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382433 2015-08-27
EP15382615 2015-12-11

Publications (1)

Publication Number Publication Date
PT3341379T true PT3341379T (en) 2019-12-16

Family

ID=56801893

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167575133T PT3341379T (en) 2015-08-27 2016-08-22 Inhibitors of ezh2

Country Status (31)

Country Link
US (1) US9718838B2 (en)
EP (1) EP3341379B1 (en)
JP (1) JP6704040B2 (en)
KR (1) KR20180030704A (en)
CN (1) CN107922434B (en)
AU (1) AU2016313541A1 (en)
BR (1) BR112018003108A2 (en)
CA (1) CA2994428A1 (en)
CO (1) CO2018002033A2 (en)
CR (1) CR20180104A (en)
CY (1) CY1122364T1 (en)
DK (1) DK3341379T3 (en)
DO (1) DOP2018000058A (en)
EC (1) ECSP18014798A (en)
ES (1) ES2756603T3 (en)
HR (1) HRP20192101T1 (en)
HU (1) HUE047630T2 (en)
IL (1) IL257061A (en)
LT (1) LT3341379T (en)
MD (1) MD3341379T2 (en)
ME (1) ME03650B (en)
MX (1) MX2018002484A (en)
PE (1) PE20181025A1 (en)
PH (1) PH12018500423A1 (en)
PL (1) PL3341379T3 (en)
PT (1) PT3341379T (en)
RS (1) RS59615B1 (en)
SI (1) SI3341379T1 (en)
TN (1) TN2018000058A1 (en)
TW (1) TW201718598A (en)
WO (1) WO2017035060A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20063844B (en) * 1999-04-22 2006-06-12 Biogen Idec Inc Using antagonist of integrin alpha-4 subunit for treatment of fibrosis
UY36758A (en) * 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd INHIBITORS OF THE ZESTE 2 HOMOLOGIST POTENTIATOR
EP3452483B1 (en) 2016-05-05 2020-04-01 GlaxoSmithKline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
JP2019527037A (en) * 2016-06-08 2019-09-26 ジェネンテック， インコーポレイテッド Diagnosis and treatment methods for cancer
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
CN109942556A (en) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 Pyrimidinone compound and its application
HUE059536T2 (en) 2018-01-31 2022-11-28 Mirati Therapeutics Inc Prc2 inhibitors
WO2019206155A1 (en) * 2018-04-24 2019-10-31 上海海雁医药科技有限公司 Ezh2 inhibitor and pharmaceutically acceptable salts and polymorphic substances thereof, and application of ezh2 inhibitor
CN112399857A (en) 2018-07-09 2021-02-23 盲人庇护基金会 Inhibition of PRC2 subunits treats ocular disorders
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN111909157B (en) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 EZH2 inhibitors and uses thereof
CN114269748A (en) 2019-06-05 2022-04-01 米拉蒂医疗股份有限公司 Imidazo [1,2-c ] pyrimidine derivatives as PRC2 inhibitors for the treatment of cancer
ES3047933T3 (en) * 2019-08-16 2025-12-05 Cyclacel Pharmaceuticals Inc Process for the preparation of a pyrimidino-diazepine derivative
CN116239519A (en) * 2023-02-20 2023-06-09 安徽峆一药业股份有限公司 A kind of synthetic method of (2-benzyloxy-4,6-dimethylpyridin-3-yl)methanol

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1303261B1 (en) * 2000-07-24 2005-03-09 Pharmacia & Upjohn Company Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
EP1414804A1 (en) * 2000-10-20 2004-05-06 Bristol-Myers Squibb Pharma Company Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors
CA2461227C (en) * 2001-09-24 2012-05-15 Jessie L.-S Au Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
EP1620449A4 (en) 2003-02-14 2008-10-01 Smithkline Beecham Corp Differentially expressed nucleic acids that correlate with ksp expression
EP2566328B1 (en) 2010-05-07 2015-03-04 GlaxoSmithKline LLC Indazoles
ES2528269T3 (en) 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
EP2566327B1 (en) 2010-05-07 2017-03-29 Glaxosmithkline LLC Indoles
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5908493B2 (en) 2010-12-01 2016-04-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Indole
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (en) 2011-04-13 2019-10-20 Epizyme Inc Aryl- or heteroaryl-substituted benzene compounds
TWI598336B (en) 2011-04-13 2017-09-11 雅酶股份有限公司 Substituted benzene compounds
US9073924B2 (en) 2011-09-13 2015-07-07 Glaxosmithkline Llc Azaindazoles
CA2850570A1 (en) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
WO2013067302A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
KR20140095073A (en) 2011-11-04 2014-07-31 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Method of treatment
WO2013067300A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075083A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
ES2718900T3 (en) * 2012-03-12 2019-07-05 Epizyme Inc Human EZH2 inhibitors and methods of use thereof
JP6250633B2 (en) 2012-04-12 2017-12-20 ザ ケマーズ カンパニー エフシー リミテッド ライアビリティ カンパニー Can tap
MX367793B (en) 2012-04-13 2019-09-06 Epizyme Inc Combination therapy for treating cancer.
BR112014025508B1 (en) 2012-04-13 2020-11-17 Eisai R&D Management Co., Ltd. salt form of a human ezh2 histone methyltransferase inhibitor
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
WO2013181462A1 (en) * 2012-05-31 2013-12-05 Amgen Inc. Use of amg 900 for the treatment of cancer
JP6254169B2 (en) 2012-09-28 2017-12-27 ファイザー・インク Benzamide and heterobenzamide compounds
US9688665B2 (en) 2012-10-15 2017-06-27 Epizyme, Inc. Methods of treating cancer
JP6461803B2 (en) 2012-10-15 2019-01-30 エピザイム，インコーポレイティド Substituted benzene compounds
JP2016503009A (en) 2012-12-13 2016-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ ZESTE homolog 2 enhancer inhibitor
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc Combination
US9701666B2 (en) 2012-12-21 2017-07-11 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
UA111305C2 (en) * 2012-12-21 2016-04-11 Пфайзер Інк. Condensed with lactams of aryl and heteroaryl
EP2935214B1 (en) 2012-12-21 2019-02-20 Epizyme, Inc. 1,4-pyridone compounds
PL2953941T3 (en) 2013-02-11 2017-11-30 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
NZ630205A (en) * 2013-04-30 2017-03-31 Glaxosmithkline Intellectual Property (No 2) Ltd Enhancer of zeste homolog 2 inhibitors
ES2640386T3 (en) 2013-07-10 2017-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited Zeste 2 counterpart inhibitor enhancer
WO2015010078A2 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
JP2016533364A (en) 2013-10-18 2016-10-27 エピザイム，インコーポレイティド How to treat cancer
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
US9822103B2 (en) 2013-11-22 2017-11-21 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015104677A1 (en) 2014-01-10 2015-07-16 Piramal Enterprises Limited Heterocyclic compounds as ezh2 inhibitors
RS60022B1 (en) 2014-03-17 2020-04-30 Daiichi Sankyo Co Ltd 1,3-benzodioxole derivatives as ezh1 and/or ezh2 inhibitors
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
LT3157527T (en) 2014-06-17 2023-07-25 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
BR112016029612B1 (en) 2014-06-17 2021-01-19 Pfizer Inc. substituted dihydroisoquinolinone compounds
SG11201610610YA (en) 2014-06-19 2017-01-27 Sloan Kettering Inst Cancer Biomarkers for response to ezh2 inhibitors
US20170217941A1 (en) 2014-06-25 2017-08-03 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
CN107148419A (en) 2014-10-28 2017-09-08 葛兰素史密斯克莱知识产权（第2 号）有限公司 The inhibitor of ZESTE enhancers homologue 2
AR102767A1 (en) 2014-12-05 2017-03-22 Lilly Co Eli EZH2 INHIBITORS
WO2016102493A1 (en) 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors
WO2016130396A1 (en) 2015-02-13 2016-08-18 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2016140501A1 (en) 2015-03-04 2016-09-09 Kainos Medicine, Inc. Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors
UY36758A (en) 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd INHIBITORS OF THE ZESTE 2 HOMOLOGIST POTENTIATOR

Also Published As

Publication number Publication date
WO2017035060A1 (en) 2017-03-02
CN107922434B (en) 2020-06-19
US9718838B2 (en) 2017-08-01
AU2016313541A1 (en) 2018-02-15
CA2994428A1 (en) 2017-03-02
BR112018003108A2 (en) 2018-09-25
CN107922434A (en) 2018-04-17
EP3341379A1 (en) 2018-07-04
ME03650B (en) 2020-07-20
TN2018000058A1 (en) 2019-07-08
CR20180104A (en) 2018-04-24
KR20180030704A (en) 2018-03-23
HUE047630T2 (en) 2021-12-28
ECSP18014798A (en) 2018-04-30
SI3341379T1 (en) 2019-11-29
DOP2018000058A (en) 2018-03-30
EP3341379B1 (en) 2019-10-09
PH12018500423A1 (en) 2018-08-29
LT3341379T (en) 2019-12-10
MX2018002484A (en) 2018-06-15
JP6704040B2 (en) 2020-06-03
IL257061A (en) 2018-03-29
JP2018530527A (en) 2018-10-18
MD3341379T2 (en) 2020-01-31
CO2018002033A2 (en) 2018-05-21
US20170066780A1 (en) 2017-03-09
CY1122364T1 (en) 2021-01-27
PL3341379T3 (en) 2020-05-18
HRP20192101T1 (en) 2020-02-21
PE20181025A1 (en) 2018-06-27
RS59615B1 (en) 2020-01-31
ES2756603T3 (en) 2020-04-27
DK3341379T3 (en) 2019-12-02
TW201718598A (en) 2017-06-01

Similar Documents

Publication Publication Date Title
IL288519A (en) Inhibitors of ret
IL251584A0 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
IL259354B (en) Inhibitors of cxcr2
IL246902A0 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
IL257061A (en) Inhibitors of ezh2
ZA201700304B (en) Spirocycloheptanes as inhibitors of rock
ZA201604272B (en) Inhibitors of glutaminase
IL259801A (en) Inhibitors of ezh2 and methods of use thereof
IL259796A (en) Aza-benzimidazole inhibitors of pad4
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
AU2016205137B2 (en) Furoquinolinediones as inhibitors of TDP2
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
AU2015903172A0 (en) Inhibitors of necroptosis
AU2015900416A0 (en) Inhibitors of necroptosis